In a nutshell This study evaluated the effectiveness and safety of the R-CyBorD (rituximab, cyclophosphamide, bortezomib, dexamethasone) regimen in patients with relapsed indolent (painless) non-Hodgkin’s lymphoma (NHL). This study concluded that this regimen is effective and well-tolerated in these patients. Some background There are many...
Read More
In a nutshell This study aimed to investigate the effectiveness of obinutuzumab and venetoclax after bendamustine treatment in patients with chronic lymphocytic leukemia (CLL). This study concluded that this sequence of treatment caused no unexpected side effects. It also concluded that the outcomes were comparable to established therapies for CLL. Some...
Read More
In a nutshell This article reviewed new treatment options for patients with relapsed Hodgkin’s lymphoma (HL). Some background The most common front-line (primary) chemotherapy regimen for the treatment of HL is ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine). 88 – 94% of patients with HL respond to this treatment. However, 10...
Read More
In a nutshell This study looked at the current evidence for the effect of changing genes in T-cells (a type of immune cell) to target cancer cells in acute lymphoblastic leukemia (ALL). The study found that these T-cells were safe and effective in the treatment of ALL. Some background Acute Lymphoblastic Leukemia is a type of bone marrow cancer...
Read More
In a nutshell This article reviewed different treatment options for patients with relapsed (cancer recurrence) or refractory (does not respond to treatment) mantle cell lymphoma (MCL). Some background Chemoimmunotherapy is the typical first-line (primary) treatment for patients with MCL. 80 – 90% of patients respond to treatment, but many...
Read More
In a nutshell This study aimed to investigate the effectiveness of cabazitaxel used for patients with metastatic castration-resistant prostate cancer. This study found that patients treated with cabazitaxel had maintained or improved quality of life and pain control. Some background One treatment option for prostate cancer is androgen deprivation...
Read MoreIn a nutshell This study is investigating the best dose and effectiveness of brentuximab vedotin (Adcetris) combined with ICE (ifosfamide, carboplatin, etoposide) for Hodgkin’s lymphoma (HL) patients with relapsed or refractory (not responding to treatment) disease. The main outcomes to be measured include the tolerated dose without unacceptable...
Read More
In a nutshell This study evaluated the effectiveness and safety of second-generation tyrosine kinase (TK) inhibitors after imatinib (Gleevec) therapy in children and adolescents with chronic myeloid leukemia (CML). The authors concluded that second-generation TK inhibitors may be a viable first-line treatment option for these patients. Some background...
Read More
In a nutshell This study aimed to investigate outcomes of salvage therapy after treatment with fludarabine, cyclophosphamidine and rituximab fails in patients with chronic lymphocytic leukemia. This study concluded that salvage therapy can provide excellent outcomes for these patients. Some background Fludarabine (Fludara) is a chemotherapy used...
Read More
In a nutshell This study evaluated the safety and effectiveness of venetoclax (Venclexta) plus BR (bendamustine, rituximab) in patients with relapsed or refractory (does not respond to treatment) non-Hodgkin’s lymphoma (NHL). This study concluded that this treatment was tolerated and showed promising effectiveness in these patients. Some...
Read MoreIn a nutshell This trial compared the effectiveness of alectinib (Alecensa) against chemotherapy for treating patients with ALK-positive non-small-cell lung cancer that have progressed passed previous targeted therapy. The authors determined that alectinib was more effective than chemotherapy at treating this subgroup of patients. Some background Lung...
Read More
In a nutshell This study investigated the outcomes of umbilical cord blood transplantation in pretreated patients with Hodgkin’s lymphoma. The authors concluded that this procedure is a feasible treatment option for these patients. Some background Patients with relapsed or refractory (does not respond to treatment) Hodgkin’s lymphoma have...
Read More
